Phlebitis associated with the intravenous use of cephapirin and cephalothin in the combination therapy of antibiotics.
Phlebitis related to antibiotic infusion is one of the most frequent causes of morbidity in the debilitated patients with severe infection. There are a number of causes of infusion-induced phlebitis such as pH of intravenous fluid, needle used, and contamination of venipuncture site. Vein used to play an important role, particularly in patients with granulocytopenia receiving intravenous infusion. Cephalothin is an effective antibiotic in the treatment of granulocytopenic infection and is widely used currently. When cephalothin was introduced commercially, the frequency of phlebitis was as high as 50%. The main reason was thought to be acidity of the antibiotic solution. The cephalothin solution used currently is neutral in pH, but prevention of phlebitis is still not perfect. In contrast, cephapirin recently developed cephalosporin antibiotic, which resembles cephalothin in the antimicrobial activity and pharmacological properties caused less phlebitis than cephalothin in initial clinical studies. The patients receiving chemotherapy for malignant diseases frequently die of infections. A cephalosporin antibiotic is administered intravenously for a prolonged time in the presence of thrombocytopenia, and under such circumstances, other antibiotics such as carbenicillin (CBPC) and aminoglycoside are usually used in combination. The influence of these antibiotics injected through the same vein must be considered, but the possibility of phlebitis due to CBPC and aminoglycoside is negligible. In the present clinical study, 24 granulocytopenic patients were treated with the combination of antibiotics, cephapirin-carbenicillin-amikacin and cephalothin-carbenicillin-amikacin. Besides the clinical effect of the antibiotics, the incidence and severity of phlebitis were studied.
D000380:Agranulocytosis / Q000188:drug therapy; D002511:Cephalosporins / Q000008:administration & dosage*; D002512:Cephalothin / Q000008:administration & dosage*; D002514:Cephapirin / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D006801:Humans; D007263:Infusions, Parenteral / Q000009:adverse effects*; D010689:Phlebitis / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology*
D002511:Cephalosporins; D002514:Cephapirin; D002512:Cephalothin